Devin Quinlan
@devinquinlan
Followers
920
Following
3K
Media
18
Statuses
435
🧬🚀 Biotech VC & company creation @MPMCapital.👨🔬Biological Engineering PhD @MIT. 🙆♂️ Fmr performer/director @improvboston. he/him. 🌶 Hot takes are my own
Cambridge, MA
Joined December 2011
Grateful to be part of the "Survivor Tribal Council" of Academy Members for this year's NEVY awards in Life Sciences! Excited for the companies that were selected - hope you can join us to see the winners announced on December 5th! @NewEnglandVC
linkedin.com
The NEVCA worked with 40+ venture capital leaders across New England to identify this year's NEVY Nominees.
0
1
3
So much of scientific research is focused on bringing science fiction to life. It’s amazing how many of our most important innovations first came from the minds of writers.
This robot is alive. Incorporated into its electronics are living fungal tissues that change the robot's behavior when exposed to intense light. That and more of the best from @ScienceMagazine and science in this edition of #ScienceAdviser:
2
0
14
Great examples of why first in class and best in class are so important in our industry - there are very few drugs that win on a given mechanism, in many cases just 1. A ton of capital being spent developing insufficiently differentiated products that are perceived as “low risk”.
What's driving that bimodal distribution? Differentiation, or lack thereof. Order of entry is incredibly important for undifferentiated drugs. Conversely, it plays a far lesser role for differentiated products. In both cases, avg. benchmarks under / overstate potl. share (3/4)
2
1
31
RT @CNBCFastMoney: The disruptive potential for gene and cell therapies is taking center stage in the biotech business. @ElevateBio CEO & C….
0
4
0
Congrats to our new company Reunion Neuroscience on a $103M Series A! Reunion is a clinical-stage company developing novel psychedelic therapies for postpartum depression!.
endpoints.news
MPM BioImpact and Novo Holdings are among a group of investors pouring $103 million into a psychedelic biotech that MPM took private last summer. Reunion Neuroscience, a Morristown, NJ-based biotech...
0
0
3
What a headline! Brought me back to AP Bio. Also - a very accurate takeaway from this year's AACR. @BioCentury
0
0
3
RT @ratatat79: J&J’s William Hait highlighting the burden on pharma to launch products : 40 phase 1 ➡️ 3 BLAs! Hence $2B+ per drug launched….
0
27
0
Great writeup on DACs from @BioCentury! Lot of potential combinations of targets and payloads - looking forward to seeing the field evolve 🚀.
biocentury.com
With a series of recent deals, a splashy newco debut and a second candidate poised to enter the clinic, degrader-antibody conjugates are emerging as the ne...
0
0
1
RT @BiotechTVHQ: Company News: Nobel laureate @CarolynBertozzi on the launch of Firefly Bio and the science of degrader antibody conjugates….
0
4
0
Excited to announce our newest portfolio company - Firefly Bio! Debuting with $94M, Firefly is pioneering degrader-antibody conjugates as an evolution to ADCs. MPM co-led the Series A financing with Versant Ventures, alongside Decheng and Lilly.
fireflybiologics.com
Transformational degrader antibody conjugate company backed by founding investor Versant Ventures, MPM BioImpact, Decheng Capital and Eli Lilly
1
1
14
28% reduction in rate of heart attacks and 19% reduction in all-cause death for patients in this trial taking wegovy 🤯.
BREAKING --> Wegovy cuts risk of heart attacks in milestone cardiovascular trial via @elaineywchen $NVO $LLY #AHA23.
0
1
5
RT @MPMCapital: MPM BioImpact is pleased to participate in the Series A financing of AstronauTx to develop novel treatments for Alzheimer’s….
0
1
0
Nice article in @BioCentury on circular RNA - featuring our own @orna_tx! .
biocentury.com
Enthusiasm for RNA-based medicines remains high after the success of mRNA vaccines for COVID-19, and companies are now looking to use RNA therapies for a w...
0
1
3
It depends on your definition of bioengineering. Protein engineering, syn bio, gene editing are all making major breakthroughs. Using engineering principles to predict/model biology is limited by the quality of the measurements we can take and translatability of the assays.
Question for my bio Twitter followers: In your opinion, what are the top two reasons Biology has proven devilishly tricky to engineer?.
1
0
1
Congrats to Crossbow Therapeutics on the launch and $80M Series A! Inspired by the success of KIMMTRAK, Crossbow was founded by @MPMCapital to pioneer TCR-mimetic antibodies to tackle intracellular tumor antigens!.
biospace.com
Crossbow Therapeutics, Inc. today announced an $80 million Series A funding round led by MPM BioImpact and Pfizer Ventures, with participation from Polaris Partners, BVF Partners, Eli Lilly and...
0
0
7
Thanks to @MassBio for having me in a panel this morning discussing the investment climate and it's impact on biotech decisionmaking! . VOD:
0
0
2
Grateful to see this (finally) come out! Hope Ram can find peace & move forward.
statnews.com
For three years, nine months, and one week, MIT professor Ram Sasisekharan lived under a gag order. Now he's speaking out.
0
1
6
Scientific dishonesty is tricky to untangle, but ultimately the responsibility lies with management, especially CEO & CSO. Culture emanates from the top down and pressure to produce results creates conflicting incentives. Sprint at the killer experiments, don't avoid them.
1
3
19
RT @thebiotechclub: Thank you to Brian Goodman and @devinquinlan at @MPMCapital for hosting the Harvard Biotech Club Pitch Deck Creation Wo….
0
1
0